PAHC
Phibro Animal Health Corporation
Set alert
- YTD
- +4.07%
- 1 year
- -7.12%
- Open
- 39.38
- Prev close
- 38.86
- Mkt cap
- 1.58B
- Vol
- 182.78K
- Avg vol
- 220.26K
- EPS
- 2.43
- P/E
- 16.00
- Div yield
- 1.24%
More statistics
- Low
- 38.49
- High
- 39.95
- Forward P/E
- 10.10
- Beta
- 0.42
- Short ratio
- 4.10
- Inst. own
- 102.87%
- Dividend
- 0.48
- Ex-div date
- Sep 1, 2026
- Earnings
- Nov 4, 2026
- 50-d avg
- 36.92
- 200-d avg
- 41.27
- 1y target
- 47.00
Key statistics
- Market cap
- 1.58B
- Enterprise value
- 2.29B
- Trailing P/E
- 16.00
- Forward P/E
- 10.10
- PEG ratio
- 1.68
- Price / sales
- 1.04
- Price / book
- 4.09
- EPS (TTM)
- 2.43
- Beta
- 0.42
- Dividend yield
- 1.24%
- Payout ratio
- 19.75%
- Profit margin
- 6.57%
- Revenue (TTM)
- 1.52B
- Revenue growth
- 4.80%
- Free cash flow
- -19.30M
- Total cash
- 83.98M
- Total debt
- 795.65M
- Return on equity
- 29.72%
- Shares outstanding
- 21.11M
- Short % of float
- 7.09%
- 50-day average
- 36.92
- 200-day average
- 41.27
Analyst view
Consensus: hold
- Target (low)
- 37.00
- Target (mean)
- 47.00
- Target (high)
- 55.00
- Strong buy1
- Buy0
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.78267.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 0.783 | — | — | — |
| Aug 26, 2026 | Jun 30, 2026 | 0.713 | 0.85 | +0.14 | +19.21% |
| May 6, 2026 | Mar 31, 2026 | 0.72 | 0.76 | +0.04 | +5.56% |
| Feb 4, 2026 | Dec 31, 2025 | 0.69 | 0.87 | +0.18 | +26.09% |
| Nov 5, 2025 | Sep 30, 2025 | 0.59 | 0.73 | +0.14 | +23.73% |
| Aug 27, 2025 | Jun 30, 2025 | 0.52 | 0.57 | +0.05 | +9.62% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 14, 2026 | Citigroup | main | Neutral | Neutral |
| Apr 15, 2026 | Citigroup | init | — | Neutral |
| Nov 7, 2025 | JP Morgan | main | Overweight | Overweight |
| Aug 29, 2025 | B of A Securities | main | Underperform | Underperform |
| Jul 7, 2025 | JP Morgan | up | Neutral | Overweight |
| Jun 25, 2025 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About Phibro Animal Health Corporation
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- pahc.com
News
- Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results
- Phibro Animal Health Q4 2026 Earnings Call: Complete Transcript
- Phibro Animal Health Corp To Close Chicago Heights Facility In Summer 2027, Affecting About 100 Employees
- Phibro Animal Health Sees FY2027 Adj EPS $3.41-$3.59 vs $3.34 Est; Sees Sales $1.550B-$1.600B vs $1.548B Est
- Phibro Animal Health Appoints Daniel (Dani) Bendheim As CEO And President Effective July 1, 2026
- Citigroup Maintains Neutral on Phibro Animal Health, Lowers Price Target to $44
- Earnings Scheduled For May 6, 2026
- Phibro Animal Health Raises FY2026 Adj EPS Guidance from $2.93-$3.10 to $2.98-$3.10 vs $3.03 Est; Raises FY2026 Sales Guidance from $1.45B-$1.50B to $1.46B-$1.50B vs $1.488B Est
- Phibro Animal Health Corporation Announces Expected Implementation Of New Regulatory Framework Governing The Use Of Certain Antimicrobials In Brazil
- Citigroup Initiates Coverage On Phibro Animal Health with Neutral Rating, Announces Price Target of $62
Your note
Sign in to keep a note on PAHC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDOLINO ANTHONY | Officer and Treasurer | Stock Award(Grant) | Aug 14, 2025 | 1,793 |
| BENDHEIM DANIEL M | Chief Executive Officer | Stock Award(Grant) | Aug 5, 2026 | 15,177 |
| BENDHEIM JACK C | Officer, Director and Beneficial Owner | Stock Award(Grant) | Aug 5, 2026 | 82,792 |
| BENDHEIM JACK CLIFFORD | Chief Executive Officer | Sale | Apr 29, 2026 | 0 |
| BENDHEIM JONATHAN | Director | Stock Award(Grant) | Aug 5, 2026 | 5,984 |
| CORCORAN E. THOMAS | Director | Purchase | May 28, 2026 | 41,459 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 15.25% | 3,219,040 | 125.16M | Jun 29, 2026 |
| FMR, LLC | 14.97% | 3,160,281 | 122.87M | Jun 29, 2026 |
| State Street Corporation | 4.92% | 1,038,382 | 40.37M | Jun 29, 2026 |
| Millennium Management Llc | 4.44% | 936,701 | 36.42M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.37% | 923,318 | 35.90M | Jun 29, 2026 |
| Geode Capital Management, LLC | 3.11% | 657,350 | 25.56M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.94% | 1,253,783 | 48.75M | Sep 29, 2026 |
| Fidelity Puritan Trust-Fidelity Low-Priced Stock Fund | 3.75% | 792,401 | 30.81M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.13% | 659,626 | 25.65M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.61% | 551,536 | 21.44M | Sep 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 1.92% | 405,235 | 15.76M | Aug 30, 2026 |
| LORD ABBETT SECURITIES TRUST-Lord Abbett Value Opportunities Fund | 1.63% | 343,781 | 13.37M | Jul 30, 2026 |